In 190 checkpoint inhibitor-naïve patients with advanced oesophageal squamous cell carcinoma after one chemotherapy line, neither lomvastomig (median OS 4.8 months) nor tobemstomig (6.7) improved survival versus nivolumab (8.1).
RCTn = 190
Wyrwicz et al. A Randomized, Nivolumab-Controlled, Phase II Biomarker Study of Lomvastomig and Tobemstomig in Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus